PE-22-28, a groundbreaking peptide with promising potential in the treatment of major depressive disorder, mood regulation, and cognitive enhancement. This synthetic derivative of the naturally occurring protein Spadin offers a new approach to mental health management.

Key Features:

• Targeted Action: PE-22-28 specifically blocks the TREK-1 (TWIK-related potassium channel) receptor, a two-pore potassium channel identified as a crucial target for treating depression.
• Brain Function Regulation: This peptide plays a significant role in regulating the TREK-1 pathway in the central nervous system, particularly in areas like the prefrontal cortex and hippocampus, which are key for mood, memory, and learning.
• Rapid Neurogenesis: Remarkably, PE-22-28 induces neurogenesis in just four days, far quicker than traditional therapies, thereby accelerating the recovery process in depression treatments.
• Effective Antidepressant Properties: In vivo studies have demonstrated its potential as an antidepressant. Mice treated with PE-22-28 showed reduced signs of depression and enhanced cognitive abilities.
  
  

Benefits:

• Mood Stability and Enhancement: By binding to and blocking the TREK-1 channel, PE-22-28 produces stable and enhanced mood effects, showing more promising results than Spadin alone.
• Potential Antidepressant Alternative: Early studies suggest PE-22-28 could be an effective substitute for conventional antidepressant drugs, offering a new avenue for treating depression.
• Stroke Recovery: PE-22-28 has also shown potential in aiding recovery post-stroke, improving motor coordination, learning capacity, and maintaining long-term neurogenesis.
• Reduced Side Effects: Compared to traditional antidepressants, PE-22-28 offers a treatment option with fewer side effects.
• Enhanced Muscle Function: The peptide also contributes to increased muscle function, broadening its therapeutic scope.
• Application in Neurodegenerative Diseases: Its properties extend to aiding in the management of neurodegenerative diseases.

Applications:

• Depression Management: PE-22-28 helps manage symptoms of depression, including post-stroke depression (PSD).
• Cognitive Health: The peptide stimulates synaptogenesis and upregulates neurogenesis, contributing to improved cognitive health.
• Muscle and Neurological Health: It aids in muscle function and is beneficial for individuals with neurodegenerative diseases.

PE 22-28 COA